Real-world discontinuation rates of ocrelizumab are low, similar to pivotal trials, with rates between 3.2% and 4.1% for RRMS and PPMS. Side effects are the most common reason for discontinuation ...

Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to ...

We present a case of a woman in her 40s with disseminated enterovirus infection in the setting of maintenance therapy with ocrelizumab for relapsing-remitting multiple sclerosis. The patient ...

This was a multicenter, double-blind, randomized placebo-controlled, exploratory phase 2a study of masitinib in patients with PPMS or rfSPMS, treated over 12 months, with an extension phase ...

That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab) that inhibit B cells across the board, leaving patients prone to infections and other side ...

These changes were mainly driven by the T25FW and 9-HPT subscores, with the clinical implications being that masitinib might slow down the degeneration of lower limb function (as evidenced by a ...

That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab), which inhibit B cells across the board, leaving patients prone to infections and other side ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...